



# NFkB p65 Recombinant Rabbit Monoclonal Antibody (4-2H22L23)

<b>Product Details</b>	
Size	100 μg
Species Reactivity	Human
Published Species	Human
Host/Isotype	Rabbit / IgG
Expression system	Expi293
Class	Recombinant Monoclonal
Туре	Antibody
Clone	4-2H22L23
Conjugate	Unconjugated
Immunogen	Recombinant protein corresponding to amino acids 375-551 of NF kappaB p65
Form	Liquid
Concentration	0.5 mg/mL
Purification	Protein A
Storage buffer	PBS
Contains	0.09% sodium azide
Storage conditions	Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
RRID	AB_2532375


Applications	Tested Dilution	Publications
Western Blot (WB)	1-5 μg/mL	1 Publication
Immunohistochemistry (Paraffin) (IHC (P))	1:10-1:50	-
Immunocytochemistry (ICC/IF)	5 μg/mL	1 Publication
ChIP assay (ChIP)	1-5 μg x 10^6 cells	-

#### **Product Specific Information**

Intact IgG appears on a non-reducing gel as ~150 kDa band and upon reduction generating a ~25 kDa light chain band and a ~50 kDa heavy chain.


Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.

## Product Images For NFkB p65 Recombinant Rabbit Monoclonal Antibody (4-2H22L23)




#### NFkB p65 Antibody (701079)

Antibody specificity was demonstrated by siRNA mediated knockdown of target protein. HeLa cells were transfected with NFkB p65 siRNA and decrease in signal intensity was observed in Western Blot application using Anti-NFkB p65 Recombinant Rabbit Monoclonal Antibody (4-2H22L23) (Product # 701079). {KD}



## NFkB p65 Antibody (701079) in WB

Western blot analysis was performed on whole cell extracts (30 µg lysate) of HT-1080 (Lane 1), THP-1 (Lane 2), A431 (Lane 3), MCF7 (lane 4) and HEK-293 (lane 5). The blots were probed with Anti-NFkB p65 Recombinant Rabbit Monoclonal Antibody (Product # 701079, 2-3 µg/mL) and detected by chemiluminescence using Goat anti-Rabbit IgG (Heavy Chain) Superclonal™ Secondary Antibody, HRP conjugate (Product # A27036, 0.4 µg/mL, 1:2500 dilution). A 60 kDa band corresponding to NFkB p65 was observed across cell lines tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 10 % Bis-Tris gel (Product # NP0302BOX), XCell SureLock™ Electrophoresis System (Product # El0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with iBlot® 2 Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western blotting Substrate (Product # 32106).



#### NFkB p65 Antibody (701079)

Antibody specificity was demonstrated through detection of enrichment of the target protein at specific gene loci. Chromatin Immunoprecipitation (ChIP) was performed using anti-NFkBp65 rabbit monoclonal antibody (Product # 701079), with relevant positive (IkB, IL8) and negative target genes/binding sites(SAT2)

View more figures on thermofisher.cn

#### □ 2 References

# Western Blot (1)

#### **Biomedicines**

# gp130 Activates Mitochondrial Dynamics for Hepatocyte Survival in a Model of Steatohepatitis.

"701079 was used in Western Blotting to investigate the effect of gp130 on the components of mitochondrial dynamics in a cellular model of steatohepatitis."

Authors: Shunkina D,Dakhnevich A,Shunkin E,Khaziakhmatova O,Shupletsova V,Vulf M,Komar A,Kirienkova E, Litvinova L

**Year** 2023

Species Human

# Immunocytochemistry (1)

Laboratory investigation; a journal of technical methods and pathology

Hemoglobin oxidation generates globin-derived peptides in atherosclerotic lesions and intraventricular hemorrhage of the brain, provoking endothelial dysfunction.

"701079 was used in Immunocytochemistry-immunoflourescence to investigate if hemoglobin-derived peptides are generated during hemoglobin oxidation both in complicated atherosclerotic lesions and intraventricular hemorrhage of the brain, triggering endothelial cell dysfunction."

Authors: Posta N,Cssz É,Oros M,Peth D,Potor L,Kalló G,Hendrik Z,Sikura KÉ,Méhes G,Tóth C,Posta J,Balla G,Balla J

**Year** 2020

Species Human

Dilution 1:25

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation,"), No claim of subjected to normal, proper and intended usage. This warranty is under the product is subjected to normal, proper and intended usage in the warranty is under the product is used to supple furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES SO MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT.

BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED, ARE PLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS, AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER'S TORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER'S TORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER'S TORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER'S TORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER'S TORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER'S TORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER'S TORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER'S TORAGE AND HANDLING OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER'S TORAGE AND HANDLING OF THE